$278 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 64 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 26.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | Sell | Gilead Sciences Inc | $19,055,000 | -4.9% | 293,284 | -7.3% | 6.86% | -25.9% |
| NBIX | Sell | Neurocrine Biosciences Inc | $14,322,000 | +8.0% | 133,300 | -9.5% | 5.16% | -15.8% |
| REGN | Sell | Regeneron Pharmaceuticals | $10,825,000 | -2.0% | 28,830 | -27.6% | 3.90% | -23.6% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $9,310,000 | -6.9% | 86,141 | -15.7% | 3.35% | -27.4% |
| SGEN | Sell | Seattle Genetics Inc | $7,311,000 | +29.0% | 64,000 | -3.6% | 2.63% | +0.6% |
| INCY | Sell | Incyte Corp | $5,586,000 | -22.0% | 64,000 | -33.7% | 2.01% | -39.2% |
| PTCT | Sell | PTC Therapuetics COM | $5,470,000 | -31.5% | 114,000 | -51.7% | 1.97% | -46.6% |
| SGMO | Sell | Sangamo Therapeutics Inc | $2,533,000 | -20.0% | 303,000 | -13.4% | 0.91% | -37.7% |
| GWPH | Sell | GW Pharmaceuticals Plcads | $1,066,000 | -53.2% | 10,200 | -48.5% | 0.38% | -63.5% |
| QURE | Sell | UNIQURE NV | $967,000 | -10.6% | 13,500 | -50.9% | 0.35% | -30.4% |
| INSM | Sell | INSMED INC | $801,000 | -87.3% | 33,600 | -90.6% | 0.29% | -90.1% |
| ARQL | Exit | Arqule INC | $0 | – | -41,000 | -100.0% | -0.14% | – |
| RGEN | Exit | REPLIGEN CORP | $0 | – | -24,000 | -100.0% | -0.85% | – |
| ABMD | Exit | Abiomed Inc | $0 | – | -11,700 | -100.0% | -0.96% | – |
| CELG | Exit | Celgene Corp | $0 | – | -171,022 | -100.0% | -7.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.